Zentalis Pharmaceuticals Stifel 2026 Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right, we're going to go ahead and get started. I'm Stephen Willey, one of the Senior Biotech Analysts here at Stifel. Very glad to have with us here presenting from Zentalis, CEO Julie Eastland. She's going to provide an overview of the company. We should have some time for Q&A. If anyone has a question, feel free to raise your hand. I'm going to turn it over to Julie.
Julie, thank you. Well, thank you.
Thank you as always. We really appreciate the opportunity here at the Stifel conference with such a great audience, and we thank you all for attending and listening to this update on Zentalis and some progress on azenosertib, WEE1 inhibitor that is in development. Before we get started, I just wanted to give you an overview as we think about WEE1. We certainly will be making forward-looking statements with estimates and forecasts, and of course, we direct you to our filings with the SEC for the risks and uncertainties associated with those statements. Maybe just on an overview perspective, I want to make sure that you all understand the strategy and the opportunity that we have been pursuing now, which remains in place, which is to bring azenosertib forward in a monotherapy setting for Cyclin E1 high expressors in the platinum-resistant ovarian cancer setting.
We have been conducting a number of trials in this setting, including the DENALI trial, in particular the part two trial, and the ASPENOVA full phase III randomized control study in the same population, and we'll talk a little bit more about that later. Azenosertib is actually a very well-defined and differentiated asset from other agents that are currently being pursued or approved in this space. Azenosertib is potentially a very first-in-class oral non-chemo, non-ADC therapy, again, for a patient population that is known biologically to have high Cyclin E1 expression, and in particular, in those that we have defined through our IHC assay and our cutoff, those that have high expression in the PROC space, and they typically do worse in earlier lines of therapy and have a poor prognosis.
There's a very high unmet need, and azenosertib offers an opportunity for patients who are coming into the platinum-resistant space to potentially have a break from chemo, be treated for an agent that is directed towards them, and go on to have response rates that are correlated to, again, to their Cyclin E1 high status. We've presented some data at ESMO just last month that continue to expand and provide proof of concept and validation that a biomarker-selected population in this setting is meaningful, and that includes overall survival data that was updated at ESMO for the DENALI part 1b trial. Again, that's a monotherapy study that was done in all comers earlier. Some of the initial data was presented in 2025 at the SGO conference, and we've updated the response rates, the overall survival, and the duration at the ESMO. We'll go through that in a minute.
We have designed multiple paths to bring azenosertib to market, as I mentioned in the DENALI trial, which could serve for potential accelerated approval, and then in addition to that, the ASPENOVA trial, which is the gold standard phase III randomized control study in the same population. We have always been focused on bringing value to azenosertib beyond monotherapy. Of course, we need proof of concept as a single agent, which we have shown consistently over a number of prior trials, and our strategy is to not only look at ovarian and PROC, but to look at azenosertib in combination with standard of care agents in earlier ovarian, which includes our MUIR trial that we will talk about today, which is currently enrolling azenosertib at a selected combination dose with bevacizumab in the second-line maintenance setting in PSOC.
We announced that we will be looking to also do a combination of azenosertib in the triple-negative breast cancer space based on very compelling preclinical data that we shared at AACR earlier this year. Importantly, we have sufficient financial resources to fund these key objectives. We have reported in Q3 approximately $229 million that will get us through the first half of 2028. That funding helps to achieve key milestones, which includes the readout of the DENALI part two dataset, which we will talk about that patient population in a minute. In addition, the enrollment in ASPENOVA and the development of additional data in these combination studies that I mentioned. This is really outlined here on this slide in terms of our pipeline. As I mentioned, the DENALI trial is a phase II trial. This was a multi-part study. Part 1b has read out and was updated at ESMO.
This was an all-comer population that retrospectively looked at patients with high Cyclin E1 expression. In addition to that, then we have been enrolling the part two of DENALI trial. In this trial, we prospectively screen for patients with Cyclin E1, and then they become eligible to enroll in this trial. So it is a prospectively identified population. This trial has three parts. We announced earlier this week that we are concluding enrollment in the DENALI trial at the end of the month, and that we will present data in the first half of the year and an outcome on this study, importantly, to serve not only as proof of concept for monotherapy in this patient population in platinum-resistant ovarian cancer, but also the value that this dataset brings in terms of its support of the ASPENOVA controlled phase III trial.
As well as we have mentioned, we believe that we can take this asset into the U.S. market, but we will be looking for a partner to help support the broadening of the value of this asset beyond PROC, and certainly from a global basis. The DENALI dataset is an important part of that dataset to enlist that type of interest. As I mentioned as well, the other trials you see below, which I talked about earlier, are ongoing, and we will provide updates to those as those progress in next year. Coming back just briefly to PROC, because this is an important and actually quite a meaningful segment of the ovarian cancer setting.
Platinum-resistant ovarian cancer worldwide, and that's in the U.S., EU4, U.K., and Japan, and that's a mouthful these days, but PROC represents about 40,000 patients across those geographies, of which approximately half of those patients are predicted to benefit from azenosertib in a platinum-resistant setting for Cyclin E1 high patients. These patients, again, as we mentioned, typically don't do as well. They have nothing but single-agent chemo after having nothing but chemo coming into this setting, and they certainly could use both a directed therapy as well as an opportunity to have a break from chemo.
In addition to that, this market, I think, is well-trodden as you think about the launch of mirvetuximab or ELAHERE, which had a very impressive launch in the first few years, again, with an opportunity for about 35% of this market, and that has generated quite a significant number of sales in the U.S. that you can see here on this slide. So definitely a meaningful commercial opportunity in PROC for azenosertib, and we look forward to helping these patients. How do we know that we think this is important from our clinical evidence over time? Just briefly here on this slide, you can see that there's a wide body of evidence of clinical data. This drug has been in over 1,000 patients in monotherapy and combination across different tumor types, so it's very well characterized in terms of the dataset that we have for safety and tolerability.
Earlier this year, we announced that we've selected the 400 milligram once a day for five days on, two days off schedule of azenosertib in monotherapy in PROC, and that was from our DENALI Part 2A cohort, which was designed to look in a 1-to-1 randomization at the difference between 300 and 400 dose. Also in that population, as you can see, the tolerability and safety here was a profile that was well managed, and importantly, is clinically relevant for patients in a setting where they have IV infusion or surgery as their choices, and here an oral therapy, that again is a non-chemotherapy, is an important part, I think, of the armament for physicians and patients in this population. I want to turn your attention just briefly to the data that was presented and updated. These are the patient characteristics from the DENALI Part 1B.
Again, this was an all-comer population, and what you see here represents all patients in this setting. These were more heavily pre-treated patients with one to five prior lines of therapy, with over 60% of these patients having a median of three prior lines. In addition, the majority of patients had seen bevacizumab, PARP inhibitor, and importantly, about 50% of these patients retrospectively were defined as Cyclin E1 high. Taking a closer look at the activity of the patients who were defined as Cyclin E1 positive, this chart here shows you both activity and a waterfall of the response rates, as well as on the right, the KM curves of the overall survival. On the left, you can see that at ESMO, we slightly updated the overall response here from the prior study, which brought the overall response rate up to 37 for response evaluable.
This included an additional patient post the prior cutoff that had a response. In addition to that, you see the deep and meaningful responses in these patients in this monotherapy at the 400 milligram 5/2 dose setting. On the right, you can see the overall survival curves. The top curve is the overall survival for patients that were Cyclin E1 high. This represented about 16 months of overall survival in a population of single-agent chemotherapy that one would expect in an all-comer population to be around 12 months. In addition to that, the bottom curve is in the Cyclin E1 negative patients, where you can see they did not do as well at seven and a half months of overall survival.
Importantly, this data really helps to continue to validate and stress that this biomarker-selected population is a significant population that has responses and meaningful activity and overall survival data here in this PROC population. Turning to tolerability, there was not much update here from the prior study, but importantly, we want to point out a couple things. From the 400 milligram doses, you can see here majority of the treatment-related adverse events that we study, which include the hematological treatment-related adverse events, gastrointestinal, and others, in particular fatigue. In the light blue bars, these are grade 1 and 2, or low-grade related events. In the dark blue bar, you see that there are relatively few or low-grade, or low number, low incidence of grade 3 or higher related events.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
